Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis

Duan, Xiyu; Dong, Na; Zhang, Ti; Li, Qiang

doi:10.1007/s00432-011-1008-y

Cited by 25 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study with a high percentage of these patients up to 33% recurrence of liver metastasis was stated [26]. The above-mentioned problem with inhomogeneous and small study populations progresses further when taking alternative treatments such as transarterial chemoembolisation and radiofrequency ablation into account [46–48]. …”

Section: Discussionmentioning

confidence: 99%

Liver Resections of Isolated Liver Metastasis in Breast Cancer: Results and Possible Prognostic Factors

et al. 2014

View full text Add to dashboard Cite

Background. Breast cancer liver metastasis is a hematogenous spread of the primary tumour. It can, however, be the expression of an isolated recurrence. Surgical resection is often possible but controversial. Methods. We report on 29 female patients treated operatively due to isolated breast cancer liver metastasis over a period of six years. Prior to surgery all metastases appeared resectable. Liver metastasis had been diagnosed 55 (median, range 1–177) months after primary surgery. Results. Complete resection of the metastases was performed in 21 cases. The intraoperative staging did not confirm the preoperative radiological findings in 14 cases, which did not generally lead to inoperability. One-year survival rate was 86% in resected patients and 37.5% in nonresected patients. Significant prognostic factors were R0 resection, low T- and N-stages as well as a low-grade histopathology of the primary tumour, lower number of liver metastases, and a longer time interval between primary surgery and the occurrence of liver metastasis. Conclusions. Complete resection of metastases was possible in three-quarters of the patients. Some of the studied factors showed a prognostic value and therefore might influence indication for resection in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Liver Resections of Isolated Liver Metastasis in Breast Cancer: Results and Possible Prognostic Factors

et al. 2014

View full text Add to dashboard Cite

show abstract

“…A retrospective study by Duan et al reported a 1-year survival rate of 76.2% in those treated with cTACE combined with systemic chemotherapy compared to 48.1% in those treated with systemic therapy alone (p ¼ 0.027). 108 In a similar retrospective review comparing cTACE and systemic chemotherapy with chemotherapy alone, Li et al also showed a survival benefit with combined therapy (63 vs. 33.9%). 109 Data relating to the use of DEBDOX are limited.…”

Section: Thermal Ablation Of Metastatic Breast Cancermentioning

confidence: 94%

Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data

Shamimi-Noori

Gonsalves

Shaw

2017

Semin intervent Radiol

View full text Add to dashboard Cite

Metastatic liver disease is a major cause of cancer-related morbidity and mortality. Surgical resection is considered the only curative treatment, yet only a minority is eligible. Patients who present with unresectable disease are treated with systemic agents and/or locoregional therapies. The latter include thermal ablation and catheter-based transarterial interventions. Thermal ablation is reserved for those with limited tumor burden. It is used to downstage the disease to enable curative surgical resection, as an adjunct to surgery, or in select patients it is potentially curative. Transarterial therapies are indicated in those with more diffuse disease. The goals of care are to palliate symptoms and prolong survival. The indications and supporting data for thermal ablation and transarterial interventions are reviewed, technical and tumor factors that need to be considered prior to intervention are outlined, and finally several cases are presented.

show abstract

“…With surgery, the OS rate is 49-75/41-61% at 3/5 years, respectively, with a median of 3.8-5.3 years (20-24). With TACE, the OS rate was 63-76/13-48% at 1/3 years, respectively (25)(26)(27) (Table II). Although severe adverse effects are rare, Caralt et al reported that 2/12 patients (17%) suffered from bile leakage postoperatively (28).…”

Section: Discussionmentioning

confidence: 99%

Follow-up study of liver metastasis from breast cancer treated by proton beam therapy

Fukumitsu

Okumura

Numajiri

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Liver metastasis from breast cancer (LMBC) is an incurable, fatal disease with a very poor prognosis. Although various local treatments have been applied, their clinical utility has not been established. The purpose of this study was to investigate the safety and effectiveness of proton beam therapy (PBT) for the treatment of patients with LMGC. A total of 8 female patients (aged 38-63 years) with LMBC who received PBT between 2002 and 2012 were retrospectively reviewed. Patients who had tumors confined to the liver were investigated, whereas patients with extrahepatic tumors were excluded. A total of 5 patients had solitary tumors and 3 had multiple tumors. The total irradiation dose was 66-72.6 Gray equivalent [Gy relative biological effectiveness (RBE)] and 2 patients received concurrent chemotherapy or hormone therapy. The overall and progression-free survival (OS and PFS) rates, local control (LC) rate and adverse effects were investigated. All the patients completed treatment without interruption and late adverse effects of grade >3 were not observed. The OS rate was 88/73/58%, the PFS rate was 50/25/0% and the LC rate was 86/86/86% at 1/3/5 years, respectively. Thus, PBT is a safe treatment and the OS and PFS rates are comparable to those with other local treatments. PBT may be considered as an effective local treatment option for the treatment of LMBC patients. IntroductionApproximately 50% of breast cancer patients will develop distant metastasis (1,2), which is a major cause of cancer-related mortality among women (3). In most series, isolated liver metastases are found in 5-25% of the cases (1,2,4-6). As the majority of LMBC patients may have systemic disease, only a limited number of patients are candidates for local treatment.Although systemic chemotherapy regimens with new molecular-targeted agents have been developed, LMBC is an incurable, fatal disease, with a median survival of 3-15 months (5,7,8) and the management of liver metastases remains challenging. Thus, the treatment of patients with LMBC is considered as palliative. To improve the treatment outcome, various local treatments, such as surgery and transcatheter arterial chemoembolization (TACE) have been applied, in combination with chemotherapy or performed alternatively. However, the clinical utility of local treatment has not been established in LMBC; by contrast, surgery is widely considered to be a useful treatment option in liver metastasis from colorectal cancer (9).Proton beam therapy (PBT) is characterized by precisely delivering a high dose of radiation to the target, while significantly limiting the exposure of regions beyond the target. It is well known that PBT for primary liver cancer achieves excellent local control rates with few adverse effects (10-14). The preliminary outcome of 5 LMBC cases who received PBT during a maximum follow-up period of 8 years in 2012 was previously reported (15). The cases were further followed up and new patients with LMBC who were treated using PBT were included in order to investig...

show abstract

Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis

Abstract: The combined treatment of TACE and systemic chemotherapy may prolong survival for liver metastases in breast cancer after mastectomy.

Cited by 25 publications

References 26 publications

Liver Resections of Isolated Liver Metastasis in Breast Cancer: Results and Possible Prognostic Factors

Liver Resections of Isolated Liver Metastasis in Breast Cancer: Results and Possible Prognostic Factors

Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data

Follow-up study of liver metastasis from breast cancer treated by proton beam therapy

Contact Info

Product

Resources

About